Category
ADC Therapy Antibody Therapy Cell & Gene Therapy Oncolytic Virotherapy Others Protein Therapy Small Molecule Vaccine
2025/12/10Brochure Antibody Therapy Protein Therapy Oncolytic Virotherapy ...
These innovation assets include antibodies (including mAb, BsAb, and TsAb), ADCs, proteins, and cell and gene therapies.
2025/11/13Flyer Cell & Gene Therapy
Based on a pioneering mRNA/LNP delivery platform, an in vivo anti-CD18/BCMA mRNA/LNP CAR-T is being developed for autoimmune diseases.
2025/12/18Flyer Small Molecule
PARP inhibitors are currently in the preclinical development stage, aiming to address the challenges of systemic toxicity and limited blood-brain barrier (BBB) penetration.
2025/12/26Flyer Antibody Therapy
A proprietary AI-powered discovery platform can accelerate the development of next-generation multi-specific antibodies, monoclonal antibodies, and nanobodies. A broad range of PCC molecules are being developed at an accelerated pace in early-stage discovery.
2026/01/10Flyer Cell & Gene Therapy
Dual-AAV vector-based gene therapies are currently undergoing clinical trials for various conditions, including ophthalmic, neuromuscular, and inherited metabolic diseases.
2026/01/20Flyer Others
In alignment with global "sugar reduction" and "zero additive" trends, transgenic crops with high expression of sweet proteins are being developed as a systematic solution for natural sugar substitution at the source.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |